Rosiglitazone home

6 Jun 2009 Home PD(1), Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ RECORD Study Team RECORD (Home et al). Rosiglitazone evaluated for cardiac outcomes and regulation of diabetes. Rosiglitazone vs control myocardial infarction. Rosiglitazone

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from John Buse, MD, PhD Barry Goldstein, MD Philip Home, MD Richard Kahn, PhD

5 Jul 2007 Philip D. Home, D.M., D.Phil., Stuart J. Pocock, Ph.D., Henning causes associated with rosiglitazone treatment of type 2 diabetes. Full Text of Rosiglitazone, an antidiabetic agent, belongs to the class of drugs know as the and Regulation of Glycaemia in Diabetes (RECORD) trial by Home et al Home middot About Us middot Diabetes middot Multicentre Trials middot Translational Trials Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (Completed) with an ACE inhibitor (ramipril) andor a thiazolidinedione (rosiglitazone) can

Rosiglitazone evaluated for cardiovascular outcomes in oral agent

22 May 2007 Rosiglitazone RECORD study: glucose control outcomes at 18 months. P. D. Home1, N. P. Jones1, S. J. Pocock2, H. Beck-Nielsen3, 22 Feb 2013 Home Clinical Literature gt Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes

5 Jun 2009 The Lancet Home Journals . Prof Philip D Home Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylurea, 5 Jun 2009 The heart failure answer hasn39t changed, Dr. Home said, referencing Also, Dr. Nissen said, still unresolved is whether rosiglitazone is